IL2 and myocardial ischemia: This strategy is currently being adapted and tested in various disease settings, where Treg cell promotion is believed to be of potential therapeutic benefit.23–26 In this trial, we hypothesise that low-dose IL-2 (aldesleukin) can be used in IHD to increase Treg numbers and to rebalance the immune system with the overall goal of decreasing recurrent myocardial infarction and cardiovascular death.